vimarsana.com
Home
Live Updates
Phexxi® Prevented 99% of Pregnancies Per Act of Interco
Phexxi® Prevented 99% of Pregnancies Per Act of Interco
Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data
/PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial...
Related Keywords
United States ,
Amy Raskopf ,
Evofem Bioscience ,
Jack Hirschfield ,
Saundra Pelletier ,
Evofem Biosciences ,
American College Of Obstetricians ,
Securities Exchange ,
Evofem Biosciences Inc ,
Prnewswire Evofem Biosciences Inc ,
Nasdaq ,
Typical Use ,
Chief Executive Officer ,
Sexual Medicine ,
American College ,
Product Information ,
Securities Exchange Act ,
Private Securities Litigation Reform Act ,
Annual Report ,
Used Alone ,
Cochrane Database ,
Systematic Reviews ,
Nc ,